

## Sequence basis of the serotyping and subtyping efficiency of URA-A/B PCR in *Cryptococcus neoformans* and indications for one-way multilocus allelic shift

Toukas Dimitrios \*<sup>1</sup>, Kambouris Manousos E.\*<sup>2</sup>, Gaitanis George<sup>1,3</sup>, Menounos Panagiotis G.<sup>4</sup> and Velegriaki Aristeia<sup>1</sup>

1. Dept of Medical Laboratories, Fcty of Health and Caring Professions, Technological Educational Institute of Athens, Ag Spyridonos st., 12210 Athens, GREECE.

2. Mycology Laboratory, Medical School, National & Kapodistrian University of Athens  
75-77 Mikras Asias st., 11527 Athens, GREECE

3. Dermatology and Venereology Department, Medical School, University of Ioannina, S. Niarchou Av 45110, Ioannina Greece

4. Molecular Biology Laboratory, Military School of Nursing, Athens, GREECE

\* Authors of equal contribution

### Abstract

The genetic basis of the molecular subtyping of *Cryptococcus neoformans* isolates, performed by PCR-RFLP and PCR-SSCP methodologies led through sequencing and sequence alignment to the detection of Single Nucleotide Polymorphisms (SNP) with consistent allelic status and a clear direction of allelic shifting within and among the accepted subspecies taxa (varieties and serotypes). The consensus sequence allelic status of the subtyped and serotyped isolates points to the possibility of serotype transition accomplished through a gradual allelic shift. The direction of the shift is from Serotype A to Serotype AD to Serotype D, although it is unknown whether these quantal steps can be taken by the same isolate.

### Key words

*Cryptococcus neoformans*, URA5 gene, PCR, SSCP, Serotype AD, SNP, Loss-Of-Heterozygosity (LOH)

### Introduction

Cryptococcosis is a serious infection of immunocompromised patients (8, 27) and is considered an AIDS-defining infection (17, 28). Fungal meningitis, pulmonary cryptococcosis and brain cryptococcoma have high morbidity (19). Furthermore, members of the genus have a widespread environmental distribution (5, 9, 12, 13), infect the host through inhalation (15). They are carried in long distances by pigeons (18) which abound in both urban and rural environments, and occur in abundance on the leaves and bark of eucalyptus trees (5), which are planted in rural and urban areas to act as natural insect repellants. Eucalyptus leaves are also used in alleviating respiratory tract discomfort. The species *Cryptococcus neoformans* is able to propagate at body temperatures, and has by far the highest clinical significance (3, 20). Its strains are diverse in biochemical and clinical properties, which led initially to varieties and serotypes being introduced in its taxonomy (2, 4) and subsequently to major taxonomic revisions (14). The diverse clinical properties and also the broad geographical distribution of the yeast led in the development of serotype-defining methodologies applicable to minimum specimen quantities for use with clinical samples, providing rapid results. This initiated PCR-based methodologies for the detection of *Cryptococcus* (23), identification to species level (24) and serotyping (25). Since the target URA5 gene sequences are neither variety- nor serotype-defining, yet, showed some heterogeneity, as SSCP discriminated two subtypes for each homogenous serotype (26), we investigated the molecular genetic basis of this subspecific discrimination in order to define the applicability using a single PCR amplicon for both identification and typing. Such a possibility would allow rapid and low cost typing since the amplicon is already obtained by the identification procedure, thus saving time, labour, consumables and eliminating a second DNA extraction step. Moreover, establishing a SNP-dependent genetic basis, would allow mapping and characterization of these SNPs, which might permit selection of informative restriction sites for further or alternative RFLP analysis.

## Materials & Methods

### Strains

TABLE 1. Strains used as serotyped by molecular methodology and subtyped (where possible) by SSCP.

Strain No	12	42	17	23	26	35	49	19	45	61	69	77	81	82
Subtype	AI	AII	DI	DII	AIDII	AID	AIDI	DII	DI	DII	DII	DII	DII	DII

### DNA extraction

Single colonies of *Cryptococcus neoformans* (*C.n*) var. *neoformans* clinical isolates of serotypes A, D and AD, were used on multiple independent experimental occasions. Serotypes were determined by using the PCR-RFLP methodology described previously (25). Genomic DNA for genotyping and for PCR was extracted as described before (24, 25). Briefly, all yeast strains were cultured on Sabouraud dextrose agar (Difco, Detroit, MI, USA) for 48 h at 30°C. One loopful of a standard inoculation loop (Greiner, GmbH, Germany, SAL 10<sup>-3</sup>) from each culture was transferred into 1.5 ml microcentrifuge tubes containing 500 µl lysis buffer (200 mM Tris-HCl, pH 8, 250 mM NaCl, 25 mM EDTA, 0.5% sodium dodecyl sulfate) (all from Sigma St. Louis, MS, USA) and 6-8 glass beads 1.1-1.2 mm in diameter (Sherwood, St Louis, USA). The tubes were subsequently vortexed for 4 min and DNA was extracted once with phenol: chloroform : isoamyl alcohol (25 : 24 : 1 v : v : v) and once with chloroform : isoamyl alcohol (24 : 1 v : v). Nucleic acids were precipitated by adding an equal volume of cold isopropanol (Merck, Darmstadt, Germany). After centrifugation for 10 min at 8,000 g the pellet was washed in 500 µl wash buffer (76% ethanol, 10 mM ammonium acetate) and allowed to stand at room temperature for 15 min. The suspension was centrifuged at 8,000 g for 5 min at room temperature and the pellet was allowed to dry for 2-4 min. DNA was then washed in 70% ethanol and collected by centrifugation as before. The pellet was dried and resuspended, depending upon yield, in 35-50 µl sterile distilled water. (24).

### PCR primers and reaction conditions

PCR reactions were performed as described previously (25) in 100 µl volume containing 10 µl suspension of template DNA, 1.5 mM MgCl<sub>2</sub>, 0.4 mM dNTPs each (CLONTECH, Palo Alto, CA, USA), 2U *Taq* (Promega, Madison, WI, USA), 10 µl of 10× reaction buffer (10mM Tris-HCl, pH 9.0, 50mM KCl, 0.1% Triton®X-100) and 50 pmoles of each primer. The forward and reverse primers *URA5-A/B* (Interactiva Biotechnologies, Ulm, Germany) were derived from *C. neoformans URA5* gene, which generate an amplification product of 345 bp (position 1145 – 1490, GenBank accession no. M34606) and have been reported to amplify only *C. neoformans* sequences (22).

*URA5 A*: 5'-ACG GTG AGG GCG GTA CTA TG-3'

*URA5 B*: 5'-AAG ACC TCT GAA CAC CGT AC-3'

Amplification was performed in an authorized RoboCycler Gradient 96 Hot Top Combo (Stratagene, LaJolla, LA, USA) (Ericomp, San Diego, CA, USA) at 40 cycles, 1min at 94°C, 1min 30 sec at 63° C and 1min at 72°C. The products were visualised in 2.5% agarose (Sigma St. Louis, MS, USA) prepared in 0.5X TBE, stained with ethidium bromide and run for 30 min at 100V for assessment of the amplicon yield.

### PCR - SSCP analysis and sequencing

Non-radioactive SSCP analysis of the 345 bp amplification product was performed as follows: After purification with the DyeEx 2.0 spin kit-50 (Quiagen GmbH, Hilden, Germany), 5 µl of each amplification product were added to 5 µl of 95% formamide, 0.05% bromophenol blue and 0.05% xylene cyanol (all from Sigma, St. Louis, MS, USA)], heated to 95°C for 15 min and quenched on ice for 20 min to achieve almost complete denaturation. Each sample was then loaded on a 10% non-denaturing polyacrylamide gel, 29 w/w acrylamide :1,25 w/w bisacrylamide (Sigma, St. Louis, MS, USA) :5% Glycerol (Merck Darmstadt, Germany). Electrophoresis was performed at 380 V, 3 A for 22 h using the Marcophor (Pharmacia, Uppsala, Sweden) running apparatus at 12°C (P-Selecta Frigiterm 6000382, J.P Selecta S.A., Abrera, Spain) and visualised by 0,5% silver nitrate (BioRad, Munich, Germany) staining.

To cross-examine and confirm the SSCP results, all amplification products were sequenced by the automated ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and the sequences were aligned using the "Bioedit Sequence Alignment Editor" program.

Consensus sequences were determined by comparing the chromatograms of the forward and reverse

primers, wherever available, for the homogenous serotypes (namely A and D). Then, the consensus sequences were aligned and compared in four distinct levels of importance. First were compared sequences of the same serotype, subsequently the sequences of both homogenous serotypes, then the sequences of all the homogenous serotypes (A and D) were compared against the heterologous serotype (AD) strains and last came the comparison to GenBank ([www.ncbi.nih](http://www.ncbi.nih)) retrieved sequences where the corresponding serotype was indicated by the depositors.




FIGURE 1: Comparative SSCP patterns of *C. neoformans* Serotypes A, D, AD subtypes.

## Results

The A and D serotypes differed by one nonsense transition substitution in Residue No 30 and position 3 of the 10<sup>th</sup> codon. A transition heterozygosity symbol (Y or R, depending on the primer's vector) in the base calling process constitutes thus a safe indicator for AD serotype.

The A<sub>1</sub> and A<sub>2</sub> subtypes were found to differ by one nonsense transition substitution in Residue No 75 and position 3 of the 25<sup>th</sup> codon. This biallelic SNP's status differentiated A<sub>2</sub> from A<sub>1</sub>, D<sub>1</sub> and D<sub>2</sub>, all of which were clustered together as they shared the same allele. A transition heterozygosity symbol (Y or R, depending on the primer's vector) in the base calling process constitutes thus a safe indicator for A<sub>2</sub>D<sub>x</sub> subtype, whereas a homozygotic A or T (depending on the primer's vector) indicates a A<sub>1</sub>D<sub>x</sub> subtype.

The comparison between D<sub>1</sub> and D<sub>2</sub> subtypes revealed a strikingly different picture. The most important finding is the presence of 13 nonsense transition mutations (biallelic SNPs), all being in-frame at the 3<sup>rd</sup> residue of the respective codons (residues 60, 69, 87, 117, 132, 135, 228, 249, 252, 255, 258, 270, 279). The 13 transitions observed between D<sub>1</sub> and D<sub>2</sub> cluster D<sub>1</sub> along with A<sub>1</sub> and A<sub>2</sub> and apart from D<sub>2</sub>. A nonsense transversion mutation at Residue 319 (1<sup>st</sup> position of 107<sup>th</sup> codon) also clusters D<sub>2</sub> apart from A<sub>1</sub>, A<sub>2</sub> and D<sub>1</sub> which shared the same allele. The transversion heterozygosity symbol (K or M, depending on the primer's vector) in the base calling process constitutes thus a safe indicator for A<sub>x</sub>D<sub>2</sub> subtype, whereas a homozygotic C or G (depending on the primer's vector) indicates a A<sub>x</sub>D<sub>1</sub> subtype.

.....10.....20.....30.....40.....50.....60.....70.....75.....80

AI → ACGTGAGGGCTTTACTATGGTCTGGTGCACCTCTCAAGGGACGAATCGTCATCATCGATGATGTTCTCACCTCTGGCAAG

AII → ACGTGAGGGCTTTACTATGGTCTGGTGCACCTCTCAAGGGACGAATCGTCATCATCGATGATGTTCTCACCTCCGGCAAG

DI → ACGTGAGGGCTTTACTATGGTCTGGTGCCTCTCAAGGGACGAATCGTCATCATCGATGATGTTCTCACCTCTGGCAAG

DII → ACGTGAGGGCTTTACTATGGTCTGGTGCCTCTCAAGGGACGAATCGTCATCATCGACGATGTTCTCACCTCTGGCAAG

AIDII → ACGTGAGGGCTTTACTATGGTCTGGTGCRCCTCTCAAGGGACGAATCGTCATCATCGACGATGTTCTCACCTCTGGCAAG

(35) → ACGTGAGGGCTTTACTATGGTCTGGTGCRCCTCTCAAGGGACGAATCGTCATCATCGACGATGTTCTCACCTCTGGCAAG

(26) → ACGTGAGGGCTTTACTATGGTCTGGTGCRCCTCTCAAGGGACGAATCGTCATCATCGAYGATGTTCTCACCTCTGGCAAG

(49) → AGGTGAGGGCTTTACTATGGTCTGGTGCRCCTCTCAAGGGACGAATCGTCATCATCGAYGATGTTCTCACCTCTGGCAAG

.....90.....100.....110.....120.....130.....140.....150.....160.....

AI → GCCATTCGTGAAGCTATTGACATTCTCAAGGCCTCTCCTGAAGCGAAGCTCGTTGGAATTGTCCAGCTTGTGCACAGACAAG

AII → GCCATTCGTGAAGCTATTGACATTCTCAAGGCCTCTCCTGAAGCGAAGCTCGTTGGAATTGTCCAGCTTGTGCACAGACAAG

DI → GCCATTCGTGAAGCTATTGACATTCTCAAGGCCTCTCCTGAAGCGAAGCTCGTTGGAATTGTCCAGCTTGTGCACAGACAAG

DII → GCCATTCGTGAAGCTATTGACATTCTCAAGGCCTCCCTGAAGCGAAGCTTGTCCGGAATTGTCCAGCTTGTGCACAGACAAG

AIDII → GCCATTCGTGAAGCTATTGACATTCTCAAGGCCTCCCTGAAGCGAAGCTTGTCCGGAATTGTCCAGCTTGTGCACAGACAAG

(35) → GCCATTCGTGAAGCTATTGACATTCTCAAGGCCTCYCCTGAAGCGAAGCTYGTGGAATTGTCCAGCTTGTGCACAGACAAG

(26) → GCCATTCGTGAAGCTATTGACATTCTCAAGGCCTCYCCTGAAGCGAAGCTYGTGGAATTGTCCAGCTTGTGCACAGACAAG

(49) → GCCATTCGTGAAGCTATTGACATTCTCAAGGCCTCYCCTGAAGCGAAGCTYGTGGAATTGTCCAGCTTGTGCACAGACAAG

.....170.....180.....190.....200.....210.....220.....228

AI → AGAAAGGCCAGAGCGGTAGCGGCAAGAGTACCGTACAGGAGGTTGAGGAAGAGTTCGGTGTGCCT

AII → AGAAAGGCCAGAGCGGTAGCGGCAAGAGTACCGTACAGGAGGTTGAGGAAGAGTTCGGTGTGCCT

DI → AGAAAGGCCAGAGCGGTAGCGGCAAGAGTACCGTACAGGAGGTTGAGGAAGAGTTCGGTGTGCC

DII → AGAAAGGCCAGAGCGGTAGCGGCAAGAGTACCGTACAGGAGGTTGAGGAAGAGTTCGGTGTGCCT

AIDII → AGAAAGGCCAGAGCGGTAGCGGCAAGAGTACCGTACAGGAGGTTGAGGAAGAGTTCGGTGTGCCT

(35) → AGAAAGGCCAGAGCGGTAGCGGCAAGAGTACCGTACAGGAGGTTGAGGAAGAGTTCGGTGTGCCT

(26) → AGAAAGGCCAGAGCGGTAGCGGCAAGAGTACCGTACAGGAGGTTGAGGAAGAGTTCGGTGTGCCY

(49) → AGAAAGGCCAGAGCGGTAGCGGCAAGAGTACCGTACAGGAGGTTGAGGAAGAGTTCGGTGTGCCY




FIGURE 2: Aligned sequence results of various subtypes (A<sub>1</sub>, A<sub>2</sub>, D<sub>1</sub>, D<sub>2</sub>, A<sub>1</sub>D<sub>11</sub>) and in-house AD strains (Strains 26, 35, 49). R=A/G, Y=C/T, M=A/C dimorphisms. Residues differentiating between D<sub>1</sub> and D<sub>2</sub> are in red, the ones differentiating between A<sub>1</sub> and A<sub>2</sub> are in green and the ones differentiating between Serotype A (A<sub>1</sub>, A<sub>2</sub>) and Serotype D (subtypes D<sub>1</sub>, D<sub>2</sub>) are in blue.

Some 6 more D<sub>2</sub> strains plus our original D<sub>2</sub>, strain 23 (included for control purposes) and one more D<sub>1</sub> strain plus our original D<sub>1</sub>, strain 17 (included for control purposes) were subsequently sequenced to assess the extent and homogeneity of the haplotypes defining D<sub>1</sub> status. The 12 of the 13 observed transitions do cluster D<sub>1</sub> along with A<sub>1</sub> and A<sub>2</sub> and apart from D<sub>2</sub>. The 13<sup>th</sup>, in Residue 69 is characteristic for only one D<sub>2</sub> strain, the No 23, while the other D<sub>2</sub> strains had the same allelic status at this position as D<sub>1</sub> and A<sub>1</sub>, A<sub>2</sub> and is thus considered recent point mutation. To our amazement, both D<sub>1</sub> strains had fully shifted in all 13 informative positions from D<sub>1</sub> to D<sub>2</sub> i.e. the whole D-informative haplotype of 12 transitions and one transversion shifted from A<sub>1</sub>/A<sub>2</sub>/D<sub>1</sub> to D<sub>2</sub>. The completeness of the shifting is absolute and there is no sequence variation, neither indel nor substitution, to distinguish the 7 D<sub>2</sub> strains from the 2 D<sub>1</sub> ones. This practically means that the Strains 17 and 45 shifted to D<sub>2</sub> haplotype at some time after predated SSCP experiments were performed, as this had happened quite some time before the second batch of sequencing experiments.

TABLE 2: Allelic status of informative residues in homogenous serotypes and selected AD-serotyped strains

Residue No	St 35 A1Dx	Str 26 A1D2	St 49 A1D1	A1 Haplotype	D2 Haplotype
30	-	R	R	A	G
60	C	Y	Y	T	C
69	C	C	C	C	T
75	T	T	T	T	T
87	C	Y	Y	T	C
117	Y	Y	Y	T	C
132	Y	Y	Y	C	T
135	Y	C	Y	T	C
228	T	Y	Y	C	T
240	T	Y	Y	C	T
252	C	Y	Y	T	C
255	Y	C	C	T	C
258	T	Y	Y	C	T
270	A	A	R	G	A
279	Y	C	Y	T	C
319	-	M	C	C	A

Going to the third level of comparison, 3 of our own AD strains (Strains 26, 35, 49) were sequenced and compared to the individual A and D sequences and with SSCP results. The interesting finding is that they were supposedly A<sub>1</sub>D<sub>1</sub> heterozygotes with observed diploidy by preceding SSCP, but the sequence alignment brought occasionally forth a A<sub>1</sub>-D<sub>2</sub> pattern. The symbols A<sub>1/2</sub>, D<sub>1/2</sub> were arbitrary introduced by us to describe SSCP subtypes within the serotypes (26). We kept the SSCP nomenclature for the homogenous serotypes and recharacterised the AD strains by sequence relevance. Sequencing has shown one of our AD strains (Strain 26) being A<sub>1</sub>D<sub>2</sub>. It bears R heterozygosity at Residue 30, the A<sub>1</sub> allele at Residue 75 and M heterozygosity at Residue 319. The second of our AD strains (Strain 49) was shown as A<sub>1</sub>D<sub>1</sub>. It bears R heterozygosity at Residue 30, the A<sub>1</sub> allele at Residue 75 and A<sub>1</sub>/A<sub>2</sub>/D<sub>1</sub> allele at Residue 319. The third AD strain (strain 35) cannot be properly subtyped by sequencing, because both Residue 30 and Residue 319 are outside the sequenced area. As at Residue 75 it bears the A<sub>1</sub> allele it can be characterized A<sub>1</sub>D<sub>x</sub> despite the lack of the informative heterozygosity at Residue 30, due to the numerous heterozygocities scored at the 12 transition spots, which clearly indicate diploidy with presence of some D<sub>2</sub> alleles. SSCP had given clear-cut A<sub>1</sub>D<sub>1</sub> patterns for all 3 strains at earlier time.

More intriguing was the fact that the expected heterozygosity was not universally present to all 12 transition spots/loci in any of the 3 strains: there were enough cases where homozygosity was observed in expected heterozygosity points, and these homozygous points were neither standard nor the same in the 3 strains. A weighted clustering of the 3 strains is possible, but no identical pairs of strains could be detected in the distribution of the heterozygosity and homozygosity observed on the 13 expected spots (12 transitions, 1 transversion). Even more intriguing is the fact that wherever a homozygosity was observed in any of the 13 positions in any of the 3 strains (a total of 16 homozygocities in 39 loci), it clearly implied a D<sub>2</sub> haplotype.

The transversion event at Residue 319, on the other hand, proved of more practical value. The chemical process of this type of mutation is more complicated and thus more stable. At strain 35, the Residue 319 lays outside the sequenced area, but at strain 26 there was a clear heterozygosity (implying A<sub>x</sub>D<sub>2</sub>) whereas at Strain 49 a clear homozygosity. The important fact is that it is the only SNP homozygosity event in the polymorphic positions not presenting the D<sub>2</sub> allele. It thus clearly implies the A<sub>1</sub>D<sub>1</sub> subtype. A SNP presenting such stability is considered the most informing, and possibly the only one necessary, for attesting D<sub>2</sub> status to a D-serotyped strain. Thus we characterized strain 49 as A<sub>1</sub>D<sub>1</sub>, in accordance to previous SSCP, and strain 26 A<sub>1</sub>D<sub>2</sub> based on the allelic status of Residue 319, in contrast to previous SSCP. In the AD strains, the haplotype transforms progressively towards D<sub>2</sub>. It is observed that only the A/D defining transition at Residue 30 and the D<sub>1</sub>/D<sub>2</sub> defining transversion of Residue 319 do not shift to homogenous D<sub>2</sub> alleles and present stability.

Of extreme importance is the fact that Strain 49 retains its A<sub>1</sub>D<sub>1</sub> characteristic allelic condition at Residue 319 despite the fact that all the other D<sub>1</sub>/D<sub>2</sub> SNP positions have either transited to A<sub>1</sub>D<sub>2</sub> heterozygosity, or (Residue 255) to homozygosity for D<sub>2</sub> allele. Contrarily, Strain 26, characterized A<sub>1</sub>D<sub>2</sub> by the transversion, has an allelic status of the 12 SNPs highly/more weighted to D<sub>2</sub>: there are 8 heterozygosities and 4 D<sub>2</sub> homozygosities. If a model of allele shifting is accepted, it somehow is asynchronous in the different positions and not needing a D<sub>2</sub> strain to initiate the shift through a LOH mechanism. A series of steps turn the SNP positions to A<sub>1</sub>D<sub>2</sub> heterozygous and subsequently to D<sub>2</sub> homozygous. At some point, when the shift (teleologically entailing 12X2= 24 steps) reaches a threshold, the character of the D<sub>1</sub> chain changes to D<sub>2</sub>, a change signaled by the transversion of Residue 319 to heterozygous status. Neither the threshold nor its nature is known, i.e. whether it entails a strictly predetermined sequence of steps or a less stringently predetermined one, with some degrees of freedom. Though, obviously some positions may conclude the transformation to full D<sub>2</sub> status with 2 transitional steps (e.g. Position 255) before the position 319 has transversed to A<sub>1</sub>D<sub>2</sub> allelic condition. Thus, it is highly recommended that to determine the subtype of a *C. neoformans* var. *neoformans* strain, one examines equivalently the allelic status at 3 positions : Residue 30, for A/D/AD serotyping, Residue 75 for A<sub>1</sub>/A<sub>2</sub> discrimination and Residue 319 for D<sub>1</sub>/D<sub>2</sub> discrimination. Regrettably the lack of A<sub>2</sub>D<sub>x</sub> strains (if existent in nature) has not allowed examination of concurrence between allelic status at positions 75 and 319 and possible dependence relations between the two and towards Position 30.

Unfortunately, the SSCP and sequencing experiments were not concomitant and thus SSCP results cannot authenticate the time variable, as between subcultures transitional events evidently take place, and perhaps more than one at a time in some cases.

The comparison of our own results to sequences deposited in the NCBI public database (GenBank) from serotyped strains showed some interesting points: First, all 6 A-serotyped strains [GenBank ([www.ncbi.nih](http://www.ncbi.nih)) Accession Nos AJ555621.1, AF248097.1/098.1/099.1/100.1/101.1] were of the A<sub>1</sub> subtype, by force of the single SNP at Position 75. Second, practically there were not AD serotypes, as at Residue 30 they were scored homozygously. Third, as far as AD serotypes are concerned, there is a clear clustering in two subtypes: 5 strains we characterize as A<sub>1</sub>D<sub>1</sub> [GenBank ([www.ncbi.nih](http://www.ncbi.nih)) Accession Nos AF032432.1- AF032436.1] and 2 strains as A<sub>1</sub>D<sub>2</sub> [GenBank ([www.ncbi.nih](http://www.ncbi.nih)) Accession Nos AF032430.1/31.1]. A<sub>1</sub> status is guaranteed by the SNP at Residue 75. D<sub>1</sub> status in the former 5 strains is clearly detected with 11 out of 12 homozygosities in the respective transition SNP positions. The transversion spot at Residue 319 is also A<sub>1</sub>D<sub>1</sub>-compatible. Only the Residue 30 presents a problem of a short, as it bears A-compatible homozygosity instead of AD heterozygosity. The intriguing thing is that the at the 2 A<sub>1</sub>D<sub>2</sub> strains none of the 14 SNP positions expected to show heterozygosity presented any. They are homozygous for the D<sub>2</sub>-compatible alleles.

In detail, at 11 of the 12 biallelic SNPs (residues 60, 87, 117, 132, 135, 249, 252, 255, 258, 270, 279) plus the ones at Residues 75 and 319 the alleles called were A<sub>1</sub>D<sub>1</sub>-compatible for all 5 A<sub>1</sub>D<sub>1</sub>-typed strains, but the allele at Residue 30 was not (homogenous A-compatible), nor the allele at Residue 228 (homogenous D<sub>2</sub>-compatible). The total was 5\*(11+3)=65 out of 5\*(12+3)=75 (86.66 % consistency rate) with steady positional distribution. For both the A<sub>1</sub>D<sub>2</sub>-typed strains, at all 12 of the 12 biallelic SNPs (residues 60, 87, 117, 132, 135, 249, 252, 255, 258, 270, 279) plus the ones at Residues 30, 75 and 319 the alleles called were homogenous D<sub>2</sub>-compatible giving a total of 2X15=30 out of 30 (100 % consistency rate). The grand total is 30+65=95 out of 30+75=105 (90.4% consistency rate). Only 5 incidents out of 105 examined positions (5.55%) are incompatible with the involved haplotypes and may point to specific reasoning. We cannot produce comparative SSCP-sequencing results for the Internet strains.

## Discussion

### *In-house AD strains*

Our own three AD-serotype strains (Strain Nos 26, 35, 49) presented a A<sub>1</sub>D<sub>2</sub>-compatible pattern. This was observed to some but not all of the originally 13 D<sub>1</sub>-D<sub>2</sub> transition spots. The detected heterozygosities could be explained only if the presence of the D<sub>2</sub> haplotype is accepted. There were no other heterozygosities relative to homogenous types at other spots in any of these strains. Moreover, the heterozygosities were confirmed by visual check of the chromograms. Thus, we are induced to accept the non-random nature of the heterozygosity incidence at the exact positions of D<sub>1</sub>-D<sub>2</sub> transitions. The only exception is the transition at Residue 69 (Fig. 2), which is unique to D<sub>2</sub> strain 23, implying either a very recent mutational event in D<sub>2</sub> (not yet passed to neither other D<sub>2</sub>, nor the A<sub>1</sub>D<sub>x</sub> types) or a peculiarity of this particular strain.

Since the existence of an A strand ( $A_1$ , by force of the single SNP at Residue 75 – Fig. 2) is beyond any doubt by both RFLP and SSCP methods, we may assume that a clear and unilateral case of loss of heterozygosity (LOH) is in power, unidirectionally but not uniformly. There is no ground to deduce this is due either to some kind of imprint or any other mechanism. Though, it is obvious that the allele shifting occurs in favour of the  $D_2$  alleles of the heterozygous positions. Moreover, this happens to different degrees (5 heterozygote positions out of 12 expected for strain 35; 7 out of 12 expected for strain 26; and 11 out of 12 for strain 49) which might imply that the process is still evolving. The difference in the distribution of these allele shifting events shows a discontinuous, possibly varied mechanism or chain of events which could not grade the 3 strains as different stages of a unique, clearly defined unidirectional process.

The 12<sup>th</sup> position (Residue 228 – Fig. 2) may be considered a real hot spot, showing no apparent consistency in its allelic status related to the subtype, due to reversal phenomena. However, this happens only in AD serotype, whereas in homogenous serotypes it shows absolute consistency. Alternatively, Residue 228 may be considered the very first position to shift to  $D_2$  allelic condition.

The 5 GenBank  $A_1D_1$  strains show at this position  $D_2$ -compatible homozygosity, which cannot be a LOH phenomenon, since the allele called ( $D_2$ ) is not present, given that no sign of  $D_2$  is detected at any of the other 11 biallelic informative loci in any of the 5 strains. It could be mutational allele shifting, perfectly explained by a Hot Spot status, occurring individually at the strain level and possibly followed by a LOH step. Or it might well be the first event towards the allele shifting. The  $A_1D_2$  strains show either the expected heterozygosity (as is the case with our respective, in-house, strains) or the recurring  $D_2$ -based homozygosity (GenBank retrieved), which in here could well be attributed to LOH causes.

#### *Sequencing-SSCP*

The comparative results of sequencing and SSCP, along with the observed allele shifting, lead to a series of questions regarding the discriminatory potential of SSCP.  $D_1$  varies from  $D_2$  in 12 recorded transition substitutions and a transversion substitution. As different subtypes have identical amplicon lengths, neither electrophoresis nor sequencing reveals  $D_1$  or  $D_2$  status lengthwise in heterozygotes. It is possible that changes at all 13 positions are needed to produce the homogenous  $D_2$  SSCP type. We do not have a serotype D example with fused haplotype, (if a diploid D serotype exists in nature) to establish possibility of existence, subtype status and threshold and kinetics of the transformation. This is rather odd, because our 3 AD strains produced a clear  $A_1D_1$  SSCP subtype, but transition-wise the haplotypes are partly  $A_1D_2$ -compatible. Furthermore, each strain demonstrates a different degree of diversion from the  $A_1D_1$  SSCP subtype.

Given that SSCP can demonstrably detect even one base substitution (7, 26), it is noteworthy that difference in 11 residues from the  $D_1$  haplotype (e.g. strain 49) does not produce for the D strands of the AD strains a conformation diverging from  $D_1$ . The same goes for the LOH phenomenon, which alters the  $A_1$  strands of all the  $A_1D_x$  strains in up to 7 residues (e.g strain 35) compared to the  $A_1$  haplotype. SSCP's inability to detect up to 11 bases' substitutions may mean either a mechanism of reversal of conformation alterations, or a stochastic mechanism. As seven positions (strain 35, with the 7 LOHs) with 4 different bases per position create  $4^7$  possible conformations, it is obvious that observing identical conformations implies a factor which drastically reduces the possible -to- probable ratio and allows a much limited number of practically probable conformations. This, in turn, raises questions about the negative discriminatory power of SSCP (though not yet for the positive one): In essence, if two sequences do look different, they are, but if they look identical they might well not be. Of course the time parameter should be well taken into account, as the results suggest a dynamic genomics status, which may turn results from different points in time irrelevant. This is nicely observed in the case of strain 17, which was typically  $D_1$  by both SSCP and sequencing, to shift fully to  $D_2$  the second time it was sequenced. It was the only case we had sequencing data at two points in time, of which the earlier point in time was solidly related to SSCP data. The genomic fluidity suggested by these data disqualifies confirmation by successive repetitions of such time-sensitive experimental protocols.

#### *Genbank retrieved AD sequences*

The lack of any heterozygocities at the GenBank-retrieved AD strain sequences might lead to one of the following four proposals: The first possibility is the strains not being actually AD and to have been mistakenly serotyped, which is rather implausible due to the maturity of the techniques. The second possibility is that they are indeed AD but haploid, at least in this part of the genome (aneuploidy). The existence of  $D_2$ - compatible allele at Residue 228 in  $A_1/D_1$ -compatible haplotypes suggests the presence of a  $D_2$  strand to impose the allele shifting (through LOH or otherwise).

The third possibility is that these strains are diploid but have reverted to a most stable condition, where LOH phenomena are completed (for the 2 A<sub>1</sub>D<sub>2</sub> strains) or barely started (for the 5 A<sub>1</sub>D<sub>1</sub> strains). It is not without importance that our own A<sub>1</sub>D<sub>x</sub> strains are highly heterozygotic, whereas the GenBank A<sub>1</sub>D<sub>x</sub> ones are homozygotic. The former show different levels of LOH, whereas the latter show complete LOH at all 15 informative loci. With the possible exception of technical allele-calling problems, a more stable genomic condition of the GenBank strains compared to our own is implied.

Such cohesiveness in status, displayed in 30 positions out of 30 at the 2 A<sub>1</sub>D<sub>2</sub> GenBank strains may indicate the fact that the process of allele shifting towards the D<sub>2</sub> haplotype is complete in these 2 strains, and thus entails a visible and deterministic outcome, of unknown time determinant. It might be that this outcome is the loss of chromosomes towards aneuploidy or haploidy which might well explain the lack of heterozygosity. The non-causative relation between amplified sequence and the serotype would make such a fact plausible. To this end, it would be interesting if RFLP data (25) or other diploidy-sensitive data were made available. Though, the 5 A<sub>1</sub>D<sub>1</sub> strains show uniformly an A-compatible allele at Residue 30. Since D<sub>1</sub> and D<sub>2</sub>, at this position, show the same allele, it becomes clear that once the 2 A<sub>1</sub>D<sub>2</sub> strains show the D-compatible allele, the D<sub>1</sub> strain is less “potent” to the A<sub>1</sub> so as to suffer, not to cause, a LOH. Such a mechanism cannot be ruled out, but it is insufficiently backed by our current data and present knowledge. The problem is that according to Residue 228 the A<sub>1</sub>D<sub>1</sub> strains start shifting to A<sub>1</sub>D<sub>2</sub>, but at the same time at Residue 30 the D<sub>1</sub> allele has shifted towards A<sub>1</sub>. The ultimate A<sub>1</sub>D<sub>2</sub> status needs a homozygous D-compatible allele at Residue 30, which makes 3 changes necessary at the same spot, which is not a very hot spot. Thus either Residue 228 is indeed a hot spot or the A-compatible homozygosity at Residue 30 is unexplained and dubious.

And the fourth possibility is the presence of a bug in the scoring of heterozygocities, either in the allele-calling or in the editing step. This would immediately put in doubt the credibility of the scoring system that typed the 5 strains as AD. Though, due to the extreme consistency in the results both horizontally (within each strain) and vertically (regarding the SNP positions) in these strains such extrapolation is rather unsubstantiated.

If heterozygocities do exist but the system fails to score them and scores forcedly a homozygosity, there must be a pattern at the ill-scored bases. A bug in base-calling at biallelic heterozygotic positions should normally create a 50%-odd consistency. The 7 AD strains with present a total of 15 positions each (highly informative residues 30, 75 and 319 and the twelve transitions) present a total of 105 informative positions. Assuming an A<sub>1</sub>D<sub>1</sub> character for the former 5 strains and an A<sub>1</sub>D<sub>2</sub> for the latter 2, we observe erroneous scoring at Residues 30 (A-homozygote instead of AD-heterozygote) and 228 (D<sub>2</sub> homozygote) for all the 5 A<sub>1</sub>D<sub>1</sub> strains. We also observe 14 cases of erroneous scoring at each of the A<sub>1</sub>D<sub>2</sub> strains, where D<sub>2</sub> homozygotes are scored instead of A<sub>1</sub>D<sub>2</sub> heterozygotes. The total is 2\*14+2\*5=38 erroneous scoring incidents out of 7\*15=105 positions (36.2%). Should a probabilistic mechanism be to blame, e.g. scoring of the allele in relative abundance in each heterozygosity as homozygote, there should be a more or less even distribution of allelic scoring in these positions or, at least, a 36.3% of erroneous results. This evenness should be at the grand total level and at each of the two degrees of freedom, i.e. vertically (per position) and horizontally (per strain). The examination vertically shows absolutely no anomalies and inconsistencies. Within each subtype, all positions were identically scored among the different strains. In the horizontal sense, the same was true for the A<sub>1</sub>D<sub>2</sub> subtype, where all the 15 positions in doubt were scored identically, in accordance to the D<sub>2</sub> haplotype. For the A<sub>1</sub>D<sub>1</sub> subtype there was a difference. One of the two misscored positions (Residue 30) was in accordance to the A<sub>1</sub> haplotype and the other (Residue 228) in accordance to D<sub>2</sub>. Thus, in 15 positions there was one anomaly 1/15, a 6.66% which becomes 3.33% if the A<sub>1</sub>D<sub>2</sub> (with no anomaly in haplotype) is taken into account. The fact that there were no inconsistencies (0% instead of the expected 50%) in the vertical sense should not be disregarded. From another perspective, the statistics were 5 anomalies to the relevant haplotypes (the Residue 228 in all 5 A<sub>1</sub>D<sub>1</sub> strains) out of 38 erratic incidents, a mere 13.15%, which represent 5.55% at the grand total of 105 positions. This suggests a direct involvement of the haplotype as a factor in the creation of erratic results. Such data exclude any notion of probabilistic mechanism in the mistyping procedure and strongly advocate a stochastic phenomenon, which may be traced rather to the editing than to the allele-calling step. A bug in the post allele-calling editing step would be expected to create exactly such extreme consistencies, whether these apply to the correct alleles (in the case of the 5 A<sub>1</sub>D<sub>1</sub> strains) or to the incorrect ones (in the case of the 2 A<sub>1</sub>D<sub>2</sub> strains).

## References

1. Βελεγράκη Α. και Καμπούρης Μ. Ε. (2003) «Μικροσυστοιχίες και Πολυπλεκτική Αλυσιδωτή Αντίδραση Πολυμεράσης: Επαναστατικές μέθοδοι Μοριακής Βιολογίας με εφαρμογές στην

- Βιοϊατρική Πράξη» *Αρχαία Ελληνικής Ιατρικής*, 20(4): 425-445.
- Bennett JE, Kwon-Chung DJ, Howard DH (1997), "Epidemiologic differences among serotypes of Cryptococcus neoformans" *Am J Epidemiol* 105, 582-6.
  - Buchanan KL, Murphy JW. 1998 "What makes Cryptococcus neoformans a pathogen?" *Emerg Infect Dis.* 4(1):71-83.
  - Canteros CE, Brudny M, Rodero L, Perrotta D, Davel G. (2002)[“Distribution of Cryptococcus neoformans serotypes associated with human infections in Argentina”] *Rev Argent Microbiol.* 34(4):213-8.
  - Ellis DH, Pfeiffer TJ. (1990) “Ecology, life cycle, and infectious propagule of Cryptococcus neoformans.” *Lancet.* 13;336 (8720):923-5.
  - Gaitanis G, Velegraki A, Alexopoulos EC, Chasapi V, Tsigonia A, Katsambas A. (2006) Distribution of Malassezia species in pityriasis versicolor and seborrhoeic dermatitis in Greece. Typing of the major pityriasis versicolor isolate M. globosa. *Br J Dermatol.*;154: 854-9.
  - Gathof BS, Sommer M, Podskarbi T, Reichardt J, Braun A, Gresser U, Shin YS. (1995) “Characterization of two stop codon mutations in the galactose-1-phosphate uridylyltransferase gene of three male galactosemic patients with severe clinical manifestation”. *Hum Genet.* 96(6) : 721-5.
  - Goldstein E, Rombo ON (1962) “Cryptococcal infection following steroid therapy” *Ann Intern Med* 56: 114
  - Ipsilantis I, Karpouzas DG et al (2008) “Effects of olive mill wastewaters on the community and function of arbuscular mycorrhizal fungi”. *1<sup>st</sup> national panhellenic congress of the “Mikrobiokosmos” Society.*
  - Kambouris M. E., Reichard U., Legakis N. J. and Velegraki A. (1999) "Sequences from the aspergillopepsin *PEP* gene of *Aspergillus fumigatus*: Evidence on their use in selective PCR identification of *Aspergillus* species in infected clinical samples". *FEMS Immunol. Med. Microbiol.* 25, 255-64.
  - Καμπούρης Μ. Ε., Βελεγράκη Α., Λεγάκης Ν. Ι. (2000) “Διαφορική διάγνωση νηματοειδών μυκήτων με άπαξ περιοριστική πέψη προϊόντων αλυσιδωτής αντίδρασης πολυμεράσης”. *Αρχαία Ελληνικής Ιατρικής* 17: 171-9.
  - Lazera MS, Pires FD, Camillo-Coura L, Nishikawa MM, Bezerra CC, Trilles L, Wanke B. (1996) “Natural habitat of Cryptococcus neoformans var. neoformans in decaying wood forming hollows in living trees” *J Med Vet Mycol.* 34(2):127-31
  - Lazera MS, Salmito Cavalcanti MA, Londero AT, Trilles L, Nishikawa MM, Wanke B. (2000) “Possible primary ecological niche of Cryptococcus neoformans” *Med Mycol* 38(5):379-83.
  - Loftus BJ, Fung E, Roncaglia P. (2005 ) “The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans”. *Science.* 25;307(5713):1321-4.
  - Lynch JP 3rd, Schaberg DR, Kissner DG, Kauffman CA (1981)“Cryptococcus laurentii lung abscess” *Am Rev Respir Dis.* 123(1):135-8.
  - Mitchell TG, Perfect JR. (1995) “Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.” *Clin Microbiol Rev.* 8(4):515-48. Review.
  - Molez J (2001 ) “The historical question of AIDS in the 1960s in Cogo river basin area in relation to cryptococcal meningitis” , *Am J Trop Med Hyg* 14: 1401-7
  - Nosanchuk JD, Rudolph J, Rosas AL, Casadevall A. (1999) “Evidence that Cryptococcus

- neoformans is melanized in pigeon excreta: implications for pathogenesis” *Infect Immun.* 67(10):5477-9
19. Perfect, J. R., and A. Casadevall. (2002) “Cryptococcosis” *Infect. Dis. Clin. N. Am.* 16:837-874.
  20. Speed B & Dunt D. (1995) “Clinical and host differences between infections with the two varieties of Cryptococcus neoformans.” *Clin Infect Dis.* 21(1):28-6.
  21. Sorrell TC, Brownlee AG, Ruma P, Malik R, Pfeiffer TJ, Ellis DH.( 1996) “Natural environmental sources of Cryptococcus neoformans var. gattii.” *J Clin Microbiol.* 34(5):1261-3.
  22. Tanaka KI, Miyazaki T et al. (1996) “Detection of Cryptococcus neoformans gene in patient with pulmonary cryptococcosis” *J Clin Microbiol* 34: 2826-8
  23. Velegraki A., Kambouris M. E. et al (1999). “Rapid extraction of fungal DNA from clinical samples for PCR amplification”. *Medical Mycol.* 37, 69-73.
  24. Velegraki A., Kambouris M. E. et al. (1999) "Identification of medically significant fungal genera by Polymerase Chain Reaction followed by Restriction Enzyme Analysis". *FEMS Immunol. Med. Microbiol.* 23, 303-12.
  25. Velegraki A, Kiosses VG et al. (2001) “Prospective use of RFLP analysis on amplified Cryptococcus neoformans URA5 gene sequences for rapid identification of varieties and serotypes in clinical samples.”. *Med Mycol* 39: 409-17.
  26. Velegraki A, Menounos PG et al (2002). “Typing Greek Clinical isolates of C. neoformans var neoformans by PCR-SSCP”. 5<sup>th</sup> *International Conference Cryptococcus & cryptococcosis, Adelaide, Australia.*
  27. Zimmerman LE, Rappaport H. (1954)” Occurrence of Cryptococcosis in patients with malignant disease of reticuloendothelial system.” *Am J Clin Pathol.* 24(9):1050-72
  28. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. (1986) “Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.” *Ann Intern Med.* 104(2):234-40

**Αλληλουχικό υπόβαθρο της οροτυποποιητικής και υποτυποποιητικής αποτελεσματικότητας της PCR με εναρκτές URA-A/B στον *Cryptococcus neoformans* και ενδείξεις για μονόδρομη πολλαπλή αλληλική εκτροπή**

Τούκας Δημήτριος\* (1), Καμπούρης Μανούσος Εμμ \*.(2), Γαϊτάνης Γεώργιος (1,3),  
Μενούνος Παναγιώτης (4) και Βελεγράκη Αριστέα (1)

(1) Τμήμα Ιατρικών Εργαστηρίων, Σχολή Επαγγελματιών Υγείας-Πρόνοιας,  
ΑΤΕΙ Αθηνών, Αγ. Σπυρίδωνος, Αιγάλεω 12210.

(2) Ειδικό Εργαστήριο Μυκητολογίας, Ιατρική Σχολή, ΕΚΠΑ, Μικράς Ασίας 75-77 Γουδή, 11527

(3) Κλινική Δερματικών και Αφροδισίων Νοσημάτων, Ιατρική Σχολή, Πανεπιστήμιο  
Ιωαννίνων, Λεωφόρος Σ. Νιάρχου, Ιωάννινα 45110

(4) Εργαστήριο Μοριακής Βιολογίας, Σχολή Αξιωματικών Αδελφών Νοσοκόμων, Αθήνα

\* Συγγραφείς ταυτόσημης συμμετοχής

### Περίληψη

Το γενετικό υπόβαθρο της μοριακής υποτυποποίησης σε στελέχη *Cryptococcus neoformans* που επιτυγχάνεται με μεθοδολογία PCR-RFLP ή PCR-SSCP οδήγησε, μέσω αλληλουχοποίησης και στοίχισης αλληλουχιών στην ανίχνευση Μονονουκλεοτιδικών Πολυμορφισμών (SNP) με σταθερό αλληλικό καθεστώς και σαφή ανυσματική αλληλική εκτροπή. Εντός και μεταξύ των καθιερωμένων υποειδικών ταξινομικών βαθμίδων (ποικιλία και ορότυπος). Ο αλληλικός τύπος των κατά σύμβαση αλληλουχιών από οροτυποποιημένα και υποτυποποιημένα στελέχη υποδεικνύει την πιθανότητα οροτυπικής υποστροφής δια βαθμιαίας αλληλικής εκτροπής. Η φορά της υποστροφής είναι από τον ορότυπο A μέσω του AD στον D, αν και παραμένει άγνωστο το αν αυτά τα βήματα μπορούν να γίνουν διαδοχικά από το ίδιο στέλεχος..

### Λέξεις -Κλειδιά

*Cryptococcus neoformans*, γονίδιο URA5, PCR, SSCP, Ορότυπος AD, Μονονουκλεοτιδικός Πολυμορφισμός (SNP), Απώλεια Ετεροζυγωτίας (LOH)